A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Latest Information Update: 10 Jan 2023
At a glance
- Drugs Ibrutinib (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms iNTEGRATE
- Sponsors Janssen Pharmaceutical KK; Pharmacyclics
- 06 Jan 2023 Primary endpoint (Final Analysis: Response Rate at 48 Weeks) has not been met, according to Results published in the Journal of Clinical Oncology.
- 06 Jan 2023 Results published in the Journal of Clinical Oncology
- 11 Jan 2022 Results published in the European Clinical Trials Database Trial Registry